tazobactam has been researched along with Blood Coagulation Disorders in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Dong, D; Li, J; Li, S; Liu, Y; Su, N; Sun, X; Tan, J; Wang, W; Wu, G; Wu, Y; Xiong, W; Yu, C; Zhang, R; Zong, Z; Zou, K | 1 |
Braun, L; Fairchok, M; Flanagan, R; Mahlen, S; Sainato, R | 1 |
2 other study(ies) available for tazobactam and Blood Coagulation Disorders
Article | Year |
---|---|
Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort study.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Blood Coagulation Disorders; Blood Platelets; Cefoperazone; Ceftazidime; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Prothrombin Time; Sulbactam; Tazobactam; Young Adult | 2020 |
Severe human parechovirus sepsis beyond the neonatal period.
Topics: Anti-Bacterial Agents; Blood Coagulation Disorders; Ceftriaxone; Enterocolitis, Necrotizing; Enzyme Inhibitors; Fever; Heart Failure; Hepatitis; Humans; Infant; Male; Parechovirus; Penicillanic Acid; Picornaviridae Infections; Piperacillin; Respiratory Insufficiency; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sepsis; Sequence Analysis, RNA; Tazobactam | 2011 |